ALKERMES, INC. for ALKERMES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Alcohol and Drug Abuse ALC
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Health Issues HCR
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.